Current and past trends in life sciences deal-making activity

Posted by Michelle Choi on Fri, May 29, 2020

Cody Powers and Christopher Shapiro co-wrote this blog post with Michelle Choi.

Access COVID-19 resources

In our last blog post, we introduced a framework to assess the impact of COVID-19 on life sciences transaction activity. We noted that, in general, transaction volume declines following recessions and market uncertainty, but there’s evidence to suggest total deal value in these cases has been less affected vs. volume, with significant larger deals observed during prior down periods. In this post, we aim to further analyze these trends and assess how they can help inform the life sciences deal-making landscape today.


>
Read More

Commercial teams: Throw out the rundown

Posted by Kumar Ritwik on Fri, May 22, 2020

Access COVID-19 resources

Amid COVID, pharma commercial teams must operate like primetime TV news crews trying to cover a breaking news story. A production rundown, which is used to orchestrate the live news broadcast on normal days, is of no use when news is breaking live. Similarly, commercial teams have their own playbooks and SOPs and must “throw out the rundown” to plan a way forward.

While the focus over the last couple of months has been on quick wins, such as setting up response teams and situation monitoring hubs, here are three ways that pharma commercial teams can prepare for the next phase:


>
Read More

How can medical and clinical teams prepare for an uncertain post-pandemic future?

Posted by Sarah Jarvis on Mon, May 18, 2020

Névine Zariffa, Founder NMD Group LLC, co-wrote this post with Sarah Jarvis

Access COVID-19 resources

The coronavirus pandemic has tested us all. It’s been humbling to have so little direct power to respond to it. For colleagues in drug development, their mission has never been so critical. Some are focused on the treatment or prevention of COVID-19, while others assess and manage the impact of the pandemic on their plans to help patients with diseases other than COVID-19. How should study teams handle the disruptions to ongoing non-COVID-19 clinical trials? How should sponsors ensure that the dissemination of scientific information is both appropriate and timely through their medical affairs organizations? When and how should companies reinitiate evidence generation activities? Such decisions benefit from scenario planning.


>
Read More

Using social media analytics to creatively gather insights

Posted by Anchal Ahuja on Mon, May 18, 2020

Sonal Singh, Pranava Goundan, and Deepak Sharma co-wrote this blog post with Anchal Ahuja.

Access COVID-19 resources

The ongoing global pandemic has been a whirlwind to say the least. Many companies want to understand the implications of COVID-19 as our day-to-day lives are being upended around the globe: How do we keep our people and customers safe? How do we enable tools and technologies to digitally connect our workforce?


>
Read More

COVID-19 vaccines: Who might win the race to the global market?

Posted by Kristyn Feldman on Fri, May 15, 2020

Samaya Krishnan, Parul Rewari, Amit Pangasa, Cody Powers and Judith Kulich co-wrote this blog post with Kristyn Feldman.

Access COVID-19 resources

In the face of the COVID-19 pandemic, the world is racing to find a safe and effective vaccine for the SARS-CoV2 virus, and industry and academic researchers have initiated clinical trials across the world to test various candidates. In upcoming blogs, we will explore the different vaccine technologies in clinical development, along with where they originated and where they might be tested and manufactured.


>
Read More